"Liquid biopsy" may help earlier detection of lung cancer treatment resistance
A blood test to regularly monitor for the presence of rearrangement of the EML4-ALK gene fusion in patients with non-small cell lung cancer (NSCLC) may help clinicians predict the outcome of treatment with crizotinib, according ...
Apr 20, 2015
0
11